Embryoman
Researchers in a 2024 study found no health problems in children born from mosaic embryo transfers, with an average age of 3 years. They also found no differences in obstetric outcomes between mosaic and euploid transfers.
The egg cell contains a high number of mitochondria, which are tiny cellular organs that produce energy that the egg needs to power fertilization and embryo development. Research has shown that these mitochondria can become dysfunctional with age, leading to reduced energy availability for the egg that could result in poor egg quality. Different treatments that target mitochondria, like antioxidant supplements or mitochondrial donation, may improve egg quality, although good quality research is lacking that shows these treatments are truly effective.
A 2024 study investigated the genetics of over 3,200 miscarriages, finding that two-thirds were associated with a chromosomal abnormality, with trisomy 16 and the 8p23.1 deletion as the most common abnormalities.
Researchers in a 2024 study found that patients that have 5 consecutive euploid transfers had a cumulative live birth rate of 98.1%, suggesting that most cases of implantation failure are due to the embryo, and that true unexplained RIF occurs in less than 2% of patients.
Researchers in a 2024 study performed an RCT and found that intraovarian PRP resulted in an increased number of eggs retrieved in patients with poor ovarian response, although these eggs weren’t more likely to become blastocysts or be euploid after PGT-A and resulted in fewer pregnancies.
Researchers in 2024 detailed a case report of a patient with recurrent implantation failure as a result of bacterial contamination, which was resolved after removal of the zona.
Researchers in a 2024 study identified what factors were involved in fertilization failure and built a nomogram (calculator) to help predict when this happens, with moderate predictive ability.
Researchers in a 2024 study found lower cumulative live birth rates in patients with a particular type of endometriosis (DIE and/or ovarian endometrioma) that was diagnosed using transvaginal ultrasound.
Researchers in a 2024 study compared the costs of patients with or without PGT-A, finding that patients younger than 35 may not benefit because of the higher chance of top-graded embryos being euploid anyway.
Researchers in a 2023 study compared PGT-A outcomes for patients with different diagnoses, including advanced maternal age (AMA), recurrent implantation failure (RIF), recurrent pregnancy loss (RPL) and severe male factor (SMF).